GlassScriptPhysician profile
Charles J Dow
NPI 1023043874
$202,409.69
in general payments reported to CMS, 2019-2025
21 companies · $36K in 2025
The $36K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $21K · 2021: $14K · 2022: $16K · 2023: $11K · 2024: $14K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Food and Beverage: $3,494 · Travel and Lodging: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,142.56 |
| Food and Beverage | $3,493.80 |
| Travel and Lodging | $2,024.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88,583.37 | 2019-2024 | |
| Novo Nordisk INC | $52,067.04 | 2021-2025 | Ozempic, Wegovy |
| Amgen INC. | $23,429.66 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $20,361.24 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $13,208.59 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $924.22 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $600.88 | 2019-2025 | |
| Vifor (International) LTD. | $500.00 | 2020 | |
| Zoll Medical Corporation | $500.00 | 2021 | |
| W. L. Gore & Associates, INC. | $425.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $411.10 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $357.32 | 2020-2025 | Onpattro |
| C. R. Bard, INC. & Subsidiaries | $320.00 | 2021 | |
| Merck Sharp & Dohme LLC | $230.37 | 2022-2025 | Verquvo |
| Esperion Therapeutics, INC. | $200.77 | 2020-2025 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $104.99 | 2021-2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $73.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.62 | 2019-2023 | Jardiance |
| Abiomed | $15.12 | 2024 | Impella |
| Amryt Pharma Holdings LTD | $12.02 | 2021 | |
| Medtronic Vascular, INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Dow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.